Show simple item record

dc.contributor.authorTerry, Martin
dc.date.accessioned2017-05-17T18:54:34Z
dc.date.available2017-05-17T18:54:34Z
dc.date.issued1992
dc.identifier.urihttps://hdl.handle.net/1813/49752
dc.description.abstractThe regulatory agencies consider oversight as appropriately applied in direct proportion to the risk associated with a given product per se, independent of the technology employed in the manufacturing process. FDA cannot legally take socioeconomic considerations into ac-count in the premarket drug approval process; animal drugs must be evaluated on the basis of the objective criteria of safety and efficacy. However, FDA does not operate in a political vacuum and in a situation where heated political debates on the socioeconomic aspects of a new animal drug run concurrently with the regulatory evaluation of the drug, it is hard to believe that the agency would not be affected to some degree in its deliberations on the drug.
dc.language.isoen_US
dc.publisherNABC
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAgricultural biotechnology
dc.subjectanimal biotechnology
dc.subjectbioethics
dc.subjectanimal well-being
dc.subjectfood safety
dc.subjectscience communication
dc.subjectagricultural indistry
dc.subjectconsumers sentimen
dc.subject
dc.titleAnimal Pharmaceuticals
dc.typebook chapter


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International

Statistics